- Home
- AVIR vs RGNX Comparison
AVIR vs RGNX Comparison
Compare AVIR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | RGNX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.9M | 418.1M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AVIR | RGNX |
|---|---|---|
| Price | $5.41 | $8.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $10.00 | ★ $28.75 |
| AVG Volume (30 Days) | 281.6K | ★ 488.4K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,367,000.00 | $10,393,000.00 |
| Revenue This Year | N/A | $51.21 |
| Revenue Next Year | N/A | $19.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $2.46 | $6.89 |
| 52 Week High | $6.45 | $16.19 |
Technical Indicators
Market Signals| Indicator | AVIR | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 41.10 |
| Support Level | $5.03 | $7.68 |
| Resistance Level | $6.37 | $9.41 |
| Average True Range (ATR) | 0.23 | 0.45 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 19.46 | 11.18 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.